Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Zymeworks Inc.
  6. Summary
    ZYME   US98985Y1082

ZYMEWORKS INC.

(ZYME)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
9.480 USD   +2.49%
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
AQ
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perform Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/30/2023 01/31/2023 02/01/2023 02/02/2023 02/03/2023 Date
9.54(c) 9.45(c) 9.27(c) 9.25(c) 9.48(c) Last
552 086 292 163 398 126 614 992 679 667 Volume
-0.42% -0.94% -1.90% -0.22% +2.49% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 241 M - -
Net income 2022 6,38 M - -
Net cash position 2022 285 M - -
P/E ratio 2022 -37,8x
Yield 2022 -
Sales 2023 53,1 M - -
Net income 2023 -116 M - -
Net cash position 2023 316 M - -
P/E ratio 2023 -7,27x
Yield 2023 -
Capitalization 611 M 611 M -
EV / Sales 2022 1,35x
EV / Sales 2023 5,56x
Nbr of Employees 286
Free-Float 86,5%
More Financials
Company
Zymeworks Inc. is a clinical-stage biopharmaceutical company that is engaged in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC... 
More about the company
Ratings of Zymeworks Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ZYMEWORKS INC.
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas..
AQ
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perfor..
MT
01/19Jazz Pharmaceuticals, Zymeworks Announce Positive Results From Phase 2 Trial of Esophag..
MT
01/19Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Pha..
CI
01/12Transcript : Zymeworks Inc. Presents at 41st Annual J.P. Morgan Healthcare Co..
CI
01/04Zymeworks Updates on Cash Resources; Chief Medical Officer to Depart Amid Internal Reor..
MT
01/04Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer
CI
01/04Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
BU
01/04HC Wainwright Adjusts Price Target on Zymeworks to $8 From $10, Maintains Neutral Ratin..
MT
2022Jazz Pharmaceuticals And Zymeworks Announce Jazz Has Confirmed Opt-In And Advances Part..
AQ
2022Barclays Adjusts Zymeworks Price Target to $9 From $7, Maintains Equal Weight Rating
MT
2022Jazz Pharmaceuticals Exercises Option to Continue Exclusive Rights to Zymeworks' Zanida..
MT
2022Zymeworks Announces Participation in Upcoming Investor Conference
BU
2022Jazz Pharmaceuticals plc and Zymeworks Announce Jazz Has Confirmed Opt-In and Advances ..
CI
More news
News in other languages on ZYMEWORKS INC.
01/19Jazz Pharmaceuticals et Zymeworks annoncent des résultats positifs de l'essai de phase ..
01/19Jazz Pharmaceuticals et Zymeworks annoncent une survie globale de 84 % à 18 mois dans l..
01/04Zymeworks fait le point sur ses liquidités ; le médecin-chef va partir dans le cadre d'..
01/04Zymeworks Inc. retire Neil Josephson du poste de médecin en chef
2022Jazz Pharmaceuticals plc et Zymeworks annoncent que Jazz a confirmé l'opt-in et fait pr..
More news
Analyst Recommendations on ZYMEWORKS INC.
More recommendations
Chart ZYMEWORKS INC.
Duration : Period :
Zymeworks Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZYMEWORKS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 9,48 $
Average target price 13,45 $
Spread / Average Target 41,9%
EPS Revisions
Managers and Directors
Kenneth Harry Galbraith Chairman & Chief Executive Officer
Neil A. Klompas Chief Financial Officer
Christopher Astle Chief Financial Officer & Senior Vice President
Paul A. Moore Chief Scientific Officer
Lota S. Zoth Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ZYMEWORKS INC.20.61%611
REGENERON PHARMACEUTICALS, INC.8.54%83 640
VERTEX PHARMACEUTICALS4.24%77 269
WUXI APPTEC CO., LTD.15.80%40 679
BIONTECH SE-5.43%34 523
BEIGENE, LTD.16.80%26 752